Novel adjuvant supplement to boost vaccine efficacy
Inventors: Jonathan Kagan
Invention Types: Therapeutics
Research Areas: Immunology
Keywords: AssayFor More Information Contact: Meyer, Abbie
Modern day vaccines that use highly purified antigens are safer and well tolerated at the expense of significantly reduced immunogenicity when compared to old fashion live or killed whole pathogen vaccines. These vaccines are often supplemented with adjuvants to produce optimal immune response. Current adjuvants in the market (i.e., alum) are effective inducing humoral immune response by boosting antibody production but are less efficient at modulating innate immunity necessary to eradicate infections. ||
Dr. Kagan’s group identified and characterized a novel fatty adjuvant oxPAPC that is able to promote dendritic cell survival and the release of cytokine interleukin-1β (IL-1β) that triggers memory T-cell production. When oxPAPC is administered subcutaneously to mice, the dendritic cells enter a “hyperactivation state” and show a 5-fold increase in adaptive immunity. Another of their key findings is that oxPAPC acts via caspase-11 to promote hyperactivation of dendritic cells.
Notably, oxPAPC is unique among known adjuvants in its ability to stimulate dendritic cells specifically, not macrophages. Both of these cell types are stimulated by all other adjuvants on the market, with macrophages being the major source of painful inflammation during vaccination, oxPAPC may facilitate the development of vaccines with less reactogenicity.
An adjuvant that activates both innate and adaptive immune systems, and increase immunogenic response to a wide range of vaccine types.
• OxPAPC selectively targets dendritic cells to induce strong memory T-cell activation with a long lasting effect that is not efficiently elicited by normal activated dendritic cells.
• May be administered nasally or orally.
• Reduced likeliness of painful inflammation during vaccination
Licensing agreement or sponsored research.
Key Publications: Zanoni et al., An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells. Science 2016 Apr 21 pii: aaf3036. [Epub ahead of print]
IPStatus: Pat. Pend.